Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
Displaying: 11 trials in your specialties ()
View trials across your selected specialties

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Healthy Volunteers, Hepatic Impairment
View Full Trial
INTERVENTION

Drug: Fedratinib

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

University of Miami Miller School of Medicine, Miami, Florida, United States

Brief Summary

This is a Phase 1, multicenter, nonrandomized, open-label, single oral dose study to assess the PK of fedratinib in subjects with moderate and severe hepatic impairment, and in matched subjects with normal hepatic function. Degrees of hepatic impairment will be determined during screening by the subject's score according to Pugh's Modification of Child's Classification of Severity of Liver Disease.

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post...
View Full Trial
INTERVENTION

Drug: Pacritinib, Drug: Physician's Choice medications

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center, Birmingham, Alabama, United States

Brief Summary

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy (approximately 116 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

A Study of APG-1252 and APG-1387 in Patients With Myelofibrosis Who Progressed After Initial Therapy

  • Status
    Not yet recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Myelofibrosis
View Full Trial
INTERVENTION

Drug: APG-1252, Drug: APG-1387, Drug: Ruxolitinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brief Summary

The study is an umbrella design focused on previously treated myelofibrosis patients divided into two population groups, based on their potential to benefit from Janus kinase 2 (JAK2) inhibitors. Group 1 will be the patients who could not achieve optimal benefit on prior JAK2 inhibitors based therapy, who could benefit when the novel agent APG-1252 or when APG-1252 plus APG-1387 are added to ruxolitinib therapy. Group 2 will be patients who cannot take either ruxolitinib or fedratinib because they cannot tolerate ruxolitinib or fedratinib or are resistant to either ruxolitinib or fedratinib. Group 1 patients will enroll into either Part 1 or Part 2, Group 2 patients will only be eligible to enroll in Part 3.

Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neop...
View Full Trial
INTERVENTION

Drug: Decitabine, Drug: Ruxolitinib, Drug: Fedratinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Brief Summary

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib and fedratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Decitabine, with ruxolitinib or fedratinib, may work better than multi-agent chemotherapy or no pre-transplant therapy, in treating patients with accelerated/blast phase myeloproliferative neoplasms.

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
View Full Trial
INTERVENTION

Drug: FEDRATINIB, Drug: Best Available Therapy (BAT)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Saint Vincent's Hospital, Darlinghurst, New South Wales, Australia

Brief Summary

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

A Study of Oral TP-3654 in Patients With Myelofibrosis

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Intermediate-2 Myelofibrosis, High-Risk Primary Myelofibrosis, Hi...
View Full Trial
INTERVENTION

Drug: TP-3654

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

NEXT Oncology, San Antonio, Texas, United States

Brief Summary

This study is a Phase 1, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 and high-risk primary or secondary MF.

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia

  • Status
    Not yet recruiting
  • Phase
    Phase 3
  • Condition
    COVID, Corona Virus Infection, Viral Pneumonia
View Full Trial
INTERVENTION

Biological: Convalescent anti-SARS-CoV-2 plasma, Drug: Sarilumab, Drug: Baricitinib, Drug: Hydroxychloroquine, Other: Injective placebo, Other: Oral placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Aalborg University Hospital, Aalborg, Denmark

Brief Summary

CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel treatment option of moderate-severe COVID-19. Participants will be randomized 1:1:1:1:1:1 to parallel treatment arms: Convalescent plasma, sarilumab, hydroxychloroquine, baricitinib, intravenous and subcutaneous placebo, or oral placebo. Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days.

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Healthy Volunteers
View Full Trial
INTERVENTION

Drug: Fedratinib, Drug: Rifampin, Drug: Efavirenz

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States

Brief Summary

This is a 2-part study to evaluate the effect of multiple doses of rifampin or efavirenz on the PK, safety, and tolerability of single doses of fedratinib in healthy subjects. Each study part will consist of a nonrandomized, fixed-sequence, open-label design. The study parts can be run in any order or in parallel. Subjects may participate in one part only. For each part, subjects will participate as follows: - Screening - Treatment period (includes baseline) - Follow-up telephone call (4 days [± 2 days] after discharge) During the study, blood samples will be collected at prespecified times for PK. Subject safety will be monitored throughout the study.

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Healthy Volunteers
View Full Trial
INTERVENTION

Drug: Fedratinib, Drug: Digoxin, Drug: Rosuvastatin, Drug: Metformin

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

PPD Phase 1 Clinic, Austin, Texas, United States

Brief Summary

This is a nonrandomized, fixed-sequence, open-label study to evaluate the effect of a single dose of fedratinib on the PK, safety, and tolerability of single doses of digoxin, rosuvastatin, and metformin in healthy subjects. The subjects will participate as follows: - Screening phase - Treatment phase (includes baseline) - Follow-up telephone call Subjects will be screened for eligibility during the screening phase. Subjects who meet all inclusion criteria and none of the exclusion criteria will return to the clinical site on Day -1 for protocol-specified assessments, and will be domiciled at the clinical site from Day -1 through the morning of Day 22. During the study, blood samples will be collected at prespecified times for PK and PD. Urine samples will be collected at prespecified times for urinary PK evaluation of metformin. Subject safety will be monitored throughout the study.

An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
View Full Trial
INTERVENTION

Drug: FEDRATINIB

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Colorado Cancer Center, Aurora, Colorado, United States

Brief Summary

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least a 35% reduction of spleen volume and one of the secondary objectives is to evaluate the safety of fedratinib